Sign Up to like & get
recommendations!
0
Published in 2021 at "Cutis"
DOI: 10.12788/cutis.0167
Abstract: Immunocompromised patients, such as organ transplant recipients, require careful benefit-risk consideration when selecting a systemic agent for psoriasis. Brodalumab is an immunomodulatory biologic that binds to and inhibits IL-17RA, thereby inhibiting the actions of IL-17A,…
read more here.
Keywords:
organ transplant;
transplant recipient;
brodalumab organ;
brodalumab ... See more keywords